Certified by Founder Lodge
DCVC Bio
United States - Palo Alto, California
INVESTOR
1 Disclosed Funding Rounds $50,000,000
13 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
DCVC Bio is a VC fund investing in early-stage computational biology startups. Advances in genetic sequencing, artificial intelligence and automation are converging to transform existing life
| Company | Date | Round | Raised |
|---|---|---|---|
 Elo Life Systems |
January, 25 ,2024 | Series A | $20,500,000 |
 Unlearn.AI |
April, 19 ,2022 | Series B | $50,000,000 |
 Ascend Gene & Cell Therapies |
May, 10 ,2023 | Series A | $132,500,000 |
 Latus Bio |
May, 03 ,2024 | Series A | $54,000,000 |
 Solu Therapeutics |
August, 01 ,2023 | Seed | $31,000,000 |
 Umoja Biopharma |
January, 21 ,2025 | Series C | $100,000,000 |
 CH4Global |
August, 30 ,2023 | Series B | $29,000,000 |
 Newleos Therapeutics |
February, 20 ,2025 | Series A | $93,500,000 |
 Radionetics Oncology |
January, 04 ,2024 | Series A | $52,500,000 |
| Elo Life Systems |
January, 25 ,2024 | Series A | $20,500,000 |
| Latus Bio |
May, 03 ,2024 | Series A | $54,000,000 |
| Umoja Biopharma |
January, 21 ,2025 | Series C | $100,000,000 |
| Newleos Therapeutics |
February, 20 ,2025 | Series A | $93,500,000 |
Cherry Ventures
Blue Bear Capital
Slow Ventures
Climate Capital
Eniac Ventures
CRESS | $234,000 | (Feb 21, 2025)
Reverb Therapeutics | $21,000,000 | (Feb 21, 2025)
Safe Intelligence | $5,253,443 | (Feb 21, 2025)
EnPlusOne Biosciences | $10,000,000 | (Feb 21, 2025)
OpenEvidence | Undisclosed Amount | (Feb 21, 2025)
